Home page > Press release
 

Authorize the processing of personal data
Edit email address
Invalid email
Email Sent
Authorize the processing of personal data
ARCHIVE PRESS RELEASE
Chiesi Group receives European Marketing Authorisation for Trimbow® inhalation powder (beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium) delivered through NEXThaler, an extrafine formulation fixed triple combination therapy fo
Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences
Chiesi Group receives the European marketing authorisation for Trimbow® (beclometasone dipropionate, formoterol fumarate, glycopyrronium) an extrafine formulation fixed triple combination therapy for the treatment of asthma
Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH).
Thomas Eichholtz appointed new Head of Global Research and Development at the Chiesi Group